Opioid therapy for chronic nonmalignant pain: A review of the critical issues

Journal of Pain and Symptom Management

Volumn 11, Issue 4, 1996, Pages 203-217

  Portenoy, Russell K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

addiction; analgesia; chronic pain; nonmalignant pain; Opioids

Indexed keywords

OPIATE AGONIST;

ANALGESIA; ANTINOCICEPTION; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; HUMAN; NONHUMAN; OPIATE ADDICTION; PRACTICE GUIDELINE; REVIEW; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0030002083     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/0885-3924(95)00187-5     Document Type: Article

References (169)

1. Brena SF, Sanders SH. Opioids in nonmalignant pain: questions in search of answers. Clin J Pain 1991;7:342-345.
2. Chabal C, Jacobson L, Chaney EF, Mariano AJ. Narcotics for chronic pain: yes or no? A useless dichotomy. APS Journal 1992;1:276-281.
3. Chabal C, Jacobson L, Chaney EF, Mariano AJ. The psychosocial impact of opioid treatment. APS Journal 1992;1:289-291.
4. Fordyce WE. Opioids, pain and behavioral outcomes. Am Pain Soc J 1992;1:282-284.
5. Gourlay GK, Cherry DA. Can opioids be successfully used to treat severe pain in nonmalignant conditions? Clin J Pain 1991;7:347-349.
6. Merry AF, Schug SA, Richards EG, Large RG. Opioids in chronic pain of nonmalignant origin: state of the debate in New Zealand. Eur J Pain 1992; 13:39-43.
7. Newman RG. The need to redefine addiction. N Engl J Med 1983;18:1096-1098.
8. Portenoy RK Opioid therapy in the management of chronic back pain. In: Tollison CD, ed. Interdisciplinary rehabilitation of low back pain. Baltimore: Williams and Wilkins, 1989:137-158.
9. Portenoy RK. Opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990;5:S46-S62.
10. Portenoy RK. Chronic opioid therapy for persistent noncancer pain: can we get past the bias? Am Pain Soc Bull 1991;1:1-5.
11. Portenoy RK. Chronic opioid therapy for non-malignant pain: from models to practice. APS Journal 1992;1:285-288.
12. Portenoy RK. Opioid therapy for chronic non-malignant pain: current status. In: Fields HL, Liebeskind JC, eds. Progress in pain research and management, vol 1. Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Seattle: IASP Publications, 1994:247-287.
13. Portenoy RK, Payne R. Acute and chronic pain. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance abuse: a comprehensive textbook. Baltimore: Williams and Wilkins, 1992:691-721.
14. Taub A. Opioid analgesics in the treatment of chronic intractable pain of non-neoplastic origin. In: Kitahata LM, Collins D, eds. Narcotic analgesics in anesthesiology. Baltimore: Williams and Wilkins, 1982:199-208.
15. Zenz M, Sorge J. Is the therapeutic use of opioids adversely affected by prejudice and law? Rec Results Cancer Res 1991;121:43-50.
16. Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia 1994;14:5-10.
17. Jorgensen L, Mortensen M-J, Jensen N-H, Eriksen J. Treatment of cancer pain patients in a multi-disciplinary pain clinic. The Pain Clinic 1990;3:83-89.
18. Moulin DE, Foley KM. Review of a hospital-based pain service. In: Foley KM, Bonica JJ, Ventafridda V, eds. Advances in pain research and therapy, vol 16. New York: Raven, 1990:413-427.
19. Portenoy RK. Cancer pain: epidemiology and syndromes. Cancer 1989;63:2298-2307.
20. Schug SA, Zech D, Dorr U. Cancer pain mangement according to WHO analgesic guidelines. J Pain Symptom Manage 1990;5:27-32.
21. Schug SA, Zech D, Grond S, Jung H, Meurser T, Stobbe B. A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992;7: 259-266.
22. Takeda F. Results of field testing in Japan of the WHO draft interim guidelines on relief of cancer pain. Pain Clinic 1986;1:83-89.
23. Toscani F, Carini M. The implementation of WHO guidelines for the treatment of advanced cancer pain at a district general hospital in Italy. The Pain Clinic 1989;3:37-48.
24. Ventafridda V, Tamburini M, DeConno F. Comprehensive treatment in cancer pain. In: Fields HL, Dubner R, Cervero F, eds. Advances in pain research and therapy, vol 9. Proceedings of the Fourth World Congress on Pain. New York: Raven, 1985:617-628.
25. Ventafridda V, Tamburini M, Caraceni A, DeConno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987;59:850-856.
26. Vijayaram S, Bhargava K, Ramamani, et al. Experience with oral morphine for cancer pain relief. J Pain Symptom Manage 1989;4:130-134.
27. Walker VA, Hoskin PJ, Hanks GW, White ID. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage 1988;3:145-149.
28. World Health Organization. Cancer pain relief. Geneva: World Health Organization, 1986.
29. World Health Organization. Cancer pain relief and palliative care. Geneva: World Health Organization, 1990.
30. Portenoy RK Pain and quality of life: theoretical aspects. In: Osoba D, ed. Quality of life in cancer patients. New York: CRC, 1991:279-292.
31. Ventafridda V, Tamburini M, Selmi S, DeConno F. Pain and quality of life assessment in advanced cancer patients. In: Ventafridda V, Van Dam FSAM, Yancik R, Tamburini M, eds. Assessment of quality of life and cancer treatment. Amsterdam: Excerpta Medica, 1986:183-192.
32. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Clinical practice guideline, no. 9. Agency for Care Policy and Research (AHCPR) publication no. 94-0592. Rockville, MD: AHCPR, US Department of Health and Human Services, Public Health Service, 1994.
33. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain, 3rd ed. Skokie, IL: American Pain Society, 1992.
34. Angell M. The quality of mercy. N Engl J Med 1982;306:98-99.
35. Health and Public Policy Committee, American College of Physicians. Drug therapy for severe chronic pain in terminal illness. Ann Intern Med 1983;99:870-873.
36. Foley KM. The relationship of pain and symptom management to patient requests for physicianassisted suicide. J Pain Symptom Manage 1991;6: 289-297.
37. McGivney WT, Crooks GM. The care of patients with severe chronic pain in terminal illness. JAMA 1984;251:1182-1188.
38. Morgan JP. American opiophobia: customary underutilization of opioid analgesics. Adv Alcohol Subst Abuse 1985;5:163-173.
39. Portenoy RK. Inadequate outcome of cancer pain treatment: influences on patient and clinician behavior. In: Patt RB, ed. Problems in cancer pain management: a comprehensive approach. Philadelphia: JB Lippincott, 1992:119-128.
40. Stjernsward J. Cancer pain relief: an important global public health issue. In: Fields HL, Dubner R, Cervero F, eds. Advances in pain research and therapy, vol 9. New York: Raven, 1985:555-558.
41. Swerdlow M, Stjernsward J. Cancer pain relief: an urgent problem. World Health Forum 1982;3: 325-330.
42. Clark HW, Sees KL. Opioids, chronic pain and the law. J Pain Symptom Manage 1993;8:297-305.
43. Haislip GR. Impact of drug abuse on legitimate drug use. In: Hill CS, Fields WS, eds. Advances in pain research and therapy, vol 11. New York: Raven, 1989:205-211.
44. Hill CS. Influence of regulatory agencies on the treatment of pain and standards of medical practice for the use of narcotics. Pain Digest 1991;1:7-12.
45. Berina LF, Guernsey BG, Hokanson JA, Doutre WH, Fuller LE. Physician perception of a triplicate prescription law. Am J Hosp Pharm 1985;42:857-859.
46. Weissman DE, Joranson DE, Hopwood MB. Wisconsin physicians' knowledge and attitudes about opioid analgesic regulations. Wis Med J 1991; 90:671-675.
47. Angarola RT, Wray SD. Legal impediments to cancer pain treatment. In: Hill CS, Fields WS, eds. Advances in pain research and therapy, vol 11. New York: Raven, 1989:213-231.
48. Edwards WT. Optimizing opioid treatment of postoperative pain. J Pain Symptom Manage 1990; 5(suppl):S24-S36.
49. Hill CS. Relationship among cultural, educational and regulatory agency influence on optimum cancer pain treatment. J Pain Symptom Manage 1990;5(suppl):S37-S45.
50. Cooper JR, Czechowicz DJ, Petersen RC, Molinari SP. Prescription drug diversion control and medical practice. JAMA 1992;268:1306-1310.
51. Portenoy RK. The effect of drug regulation on the management of cancer pain. NYS J Med 1991; 91 (suppl):13S-18S.
52. Reidenberg MM. Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State. Clin Pharmacol Ther 1991;50:129-131.
53. Gitchel GT. Existing methods to identify retail drug diversion. In: Cooper JR, Czechowicz DJ, Molinari SP, eds. Impact of prescription drug diversion control systems on medical practice and patient care. National Institute on Drug Abuse Research Monograph 131. Washington, DC: Superintendent of Documents, US Government Printing Office, 1993:132-140.
54. United States Department of Justice, Drug Enforcement Administration. Multiple copy prescription program resource guide. Washington DC: Superintendent of Documents, US Government Printing Office, 1987.
55. Jacob TR. Multiple copy prescription regulation and drug abuse: evidence from the DAWN network. In: Wilford BB, ed. Balancing the response to prescription drug abuse. Chicago: American Medical Association, 1990:205-217.
56. Sigler KA, Guernsey BG, Ingrim NB, et al. Effects on a triplicate prescription law on prescribing of Schedule II drugs. Am J Hosp Pharm 1984; 41:108-111.
57. Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991;266:2392-2397.
58. Joranson DE, Cleeland CS, Weissman DE, Gilson AM. Opioids for chronic cancer and non-cancer pain: a survey of state medical board members. Fed Bull 1992;4:15-49.
59. Arkinstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC. Efficacy of controlled-release codeine in chronic non-malignant pain: A randomized, placebo-controlled clinical trial. Pain 1995;62:169-178.
60. Moulin DE, Iezzi A, Amireh R, Sharpe WKJ, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. The Lancet 1996;347:143-147.
61. Brookoff D, Palomano R. Treating sickle cell pain like cancer pain. Ann Intern Med 1992;116: 364-368.
62. France RD, Urban BJ, Keefe FJ. Long-term use of narcotic analgesics in chronic pain. Soc Sci Med 1984;19:1379-1382.
63. Green J, Coyle M. Methadone use in the control of nonmalignant chronic pain. Pain Management 1989;Sept/Oct:241-246.
64. Kell MJ, DL Musselman. Methadone prophylaxis of intractable headaches: pain control and serum opioid levels. AJPM 1993;3:7-14.
65. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986;25:171-186.
66. Tennant FS, Uelman GF. Narcotic maintenance for chronic pain: medical and legal guidelines. Post-grad Med 1983;73:81-94.
67. Tennant FS, Robinson D, Sagherian A, Seecof R. Chronic opioid treatment of intractable non-malignant pain. Pain Management 1988;Jan/Feb:18-36.
68. Urban BJ, France RD, Steinberger DL, Scott DL, Maltbie AA. Long-term use of narcotic-antidepressant medication in the management of phantom limb pain. Pain 1986;24:191-197.
69. Zenz M, Strumpf M, Tryba M. Long-term opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992;7:69-77.
70. Buckley FP, Sizemore WA, Charlton JE. Medication management in patients with chronic nonmalignant pain: a review of the use of a drug withdrawal protocol. Pain 1986;26:153-166.
71. Finlayson RD, Maruta T, Morse BR. Substance dependence and chronic pain: profile of 50 patients treated in an alcohol and drug dependence unit. Pain 1986;26:167-174.
72. Finlayson RD, Maruta T, Morse BR, Martin MA. Substance dependence and chronic pain: experience with treatment and follow-up results. Pain 1986;26:175-180.
73. Maruta T. Prescription drug-induced organic brain syndrome. Am J Psychiatry 1978;135:376-377.
74. Maruta T, Swanson DW. Problems with the use of oxycodone compound in patients with chronic pain. Pain 1981;11:389-396.
75. Maruta T, Swanson DW, Finlayson RE. Drug abuse and dependency in patients with chronic pain. Mayo Clin Proc 1979;54:241-244.
76. McNairy SL, Maruta T, Ivnik RJ, Swanson DW, Ilstrup DM. Prescription medication dependence and neuropsychologic function. Pain 1984;18:169-177.
77. Ready LB, Sarkis E, Turner JA. Self-reported vs. actual use of medications in chronic pain patients. Pain 1982;12:285-294.
78. Turner JA, Calsyn DA, Fordyce WE, Ready LB. Drug utilization pattern in chronic pain patients. Pain 1982;12:357-363.
79. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992;49:87-91.
80. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990;43:273-286.
81. Bruera E, MacMillan D, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain 1989;37:203-210.
82. Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992;50:151-155.
83. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not in poor metabolizers of sparteine. Clin Pharmacol Ther 1990;48:686-693.
84. Arner S, Meyerson B. Opioids in neuropathic pain. Pain Digest 1993;3:15-22.
85. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23.
86. Bruera E, Macmillan K, Hanson JA, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-16.
87. Kupers RC, Konings H, Adriaensen H, Gybels JM. Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain 1991;47:5-12.
88. Cherny NI, Thaler HT, Friedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 1994;44:857-861.
89. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992;339:1367-1371.
90. McQuay HJ, Jadad AR, Carroll D, et al. Opioid sensitivity of chronic pain: a patient-controlled analgesia method. Anaesthesia 1992;47:757-767.
91. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41:1024-1028.
92. Cochin J, Kornetsky C. Development and loss of tolerance to morphine in the rat after single and multiple injections. J Pharmacol Exp Ther 1964; 145:1-20.
93. Louie AL, Way EL. Overview of opiate tolerance and physical dependence. In: Almeida OF, Shippenberg TS, eds. Neurobiology of opioids. New York: Springer-Verlag, 1991.
94. Foley KM. Clinical tolerance to opioids. In: Basbaum AI, Besson J-M, eds. Towards a new pharmacotherapy of pain. Chichester: John Wiley and Sons, 1991:181-203.
95. Foley KM. Changing concepts of tolerance to opioids: what the cancer patient has taught us. In: Chapman CR, Foley KM, eds. Current and emerging issues in cancer pain: research and practice. New York: Raven, 1993:331-350.
96. Portenoy RK. Opioid tolerance and efficacy: basic research and clinical observations. In: Gebhardt G, ed. Proceedings of the VIIth World Congress on Pain. Progress in pain research and management, vol 2. Seattle: IASP Press, 1994:595-619.
97. McQuay HJ, Bullingham RES, Moore RA. Acute opiate tolerance in man. Life Sci 1981;28:2513-2517.
98. Houde RW, Wallenstein SL, Beaver WT. Evaluation of analgesics in patients with cancer pain. In: Lasagna L, ed. International encyclopedia of pharmacology and therapeutics, section 6, vol 1. Clinical pharmacology. Oxford: Pergamon, 1966:59-98.
99. Jasinski DS. Assessment of the abuse potentiality of the morphinelike drugs (methods used in man). In: Martin WR, ed. Handbook of experimental pharmacology, vol 45: Drug addiction I. New York: Springer-Verlag, 1977:197-258.
100. Martin WR. General problems of drug abuse and drug dependence. In: Martin WR, ed. Drug addiction I. New York: Springer-Verlag, 1977:3-40.
101. Brescia FJ, Portenoy RK, Ryan M, Drasnoff L, Gray G. Pain, opioid use and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992;10:149-155.
102. Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci 1981;362:161-172.
103. Onofrio BM, Yaksh TL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg 1990;72:200-209.
104. Twycross RG. Clinical experience with diamorphine in advanced malignant disease. Int J Clin Pharmacol Ther Toxicol 1974;9:184-198.
105. Coyle N, Weaver S, Breitbart W, Portenoy RK. Delirium as a contributing factor to "crescendo" pain: three case reports. J Pain Symptom Manage 1994;9:44-47.
106. Gonzales GR, Elliot KJ, Portenoy RK, Foley KM. The impact of a comprehensive evaluation in the management of cancer pain. Pain 1991;47:141-144.
107. Schofferman J. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin. J Pain Symptom Manage 1993;8:279-288.
108. Chapman CR, Sola AE, Bonica JJ. Illness behavior and depression in pain center and private practice patients. Pain 1979;6:1-7.
109. Crook J, Tunks E. Denning the "chronic pain syndrome:" an epidemiological method. In: Fields HL, Dubner R, Cervero R, eds. Advances in pain research and therapy, vol 9. New York: Raven, 1985: 871-878.
110. Crook J, Tunks E, Rideout E, Browne G. Epidemiologic comparison of persistent pain sufferers in a specialty pain clinic and in the community. Arch Phys Med Rehabil 1986;67:451-455.
111. Crook J, Weir R, Tunks E. An epidemiological follow-up survey of persistent pain sufferers in a group family practice and specialty pain clinic. Pain 1989;36:49-61.
112. Deyo RA, Bass JE, Schoenfeld NE, Ramamurthy S. Prognostic variability among chronic pain patients: implications for study design, interpretation, and reporting. Arch Phys Med Rehabil 1988; 69:174-178.
113. Pilowsky I, Chapman CR, Bonica JJ. Pain, depression, and illness behavior in a pain clinic population. Pain 1977;4:183-192.
114. Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. JAMA 1973;223: 665-668.
115. Kreek MJ. Medical complications in methadone patients. Ann NY Acad Sci 1978;311:110-134.
116. Bruera E, Miller MJ. Non-cardiogenic pulmonary edema after narcotic treatment for cancer pain. Pain 1989;39:297-300.
117. Arora PK, Fride E, Petitto J, Waggie K, Skolnick P. Morphine-induced immune alterations in vivo. Cell Immunol 1990;126:343-353.
118. Donohoe RM, Madden JJ, Hollingsworth F, Shafer D, Falek A. Morphine depression of T cell E-rosetting: definition of the process. Fed Proc 1985;44:95-99.
119. Einstein TK, Meissler JJ, Geller EB, Adler MW. Immunosuppression to tetanus toxoid induced by implanted morphine pellets. Ann NY Acad Sci 1990;594:377-379.
120. Molitor TW, Morilla A, Risdahl JM, Murtaugh MP, Chao CC, Peterson PK. Chronic morphine administration impairs cell-mediated immune responses in swine. J Pharmacol Exp Ther 1992; 260:581-586.
121. Peterson PK, Sharp B, Gekker G, Brummit C, Keane WF. Opioid-mediated suppression of interferon-δ production by cultured peripheral blood mononuclear cells. J Clin Invest 1987;80:824-831.
122. Shavit Y, Lewis JW, Terman WG, Gale RP, Liebeskind JC. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science 1984;223:188-190.
123. Weber RJ, Ikejiri B, Rice KC, Pert A, Hagan AA. Opiate receptor mediated regulation of the immune response in vivo. National Institute of Drug Abuse Research Monograph 76. Washington, DC: Superintendent of Documents, US Government Printing Office, 1987:341-348.
124. Rounsaville BH, Novelly RA, Kleber HD, Jones C. Neuropsychological impairment in opiate addicts: risk factors. NY Acad Sci 1981;362:79-90.
125. Martin WR, Jasinski DR, Haertzen CA, et al. Methadone: a reevaluation. Arch Gen Psychiatry 1973;28:286-295.
126. Haertzen CA, Hooks NT. Changes in personality and subjective experience associated with the chronic administration and withdrawal of opiates. J Nerv Ment Dis 1969;148:606-614.
127. Banning A, Sjogren P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clin J Pain 1990;6:91-95.
128. Sjogren P, Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 1989; 39:5-12.
129. Appel PW, Gordon NB. Digit-symbol performance in methadone-treated ex-heroin addicts. Am J Psychiatry 1976;133:1337-1340.
130. Lombardo WK, Lombardo B, Goldstein A. Cognitive functioning under moderate and low dose methadone maintenance. Int J Addict 1976;11: 389-401.
131. Hendler N, Cimini C, Ma T, Long D. A comparison of cognitive impairment due to benzodiazepines and to narcotics. Am J Psychiatry 1980;137: 828-830.
132. Lowinson JH, Marion IJ, Joseph H, Dole VP. Methadone maintenance. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance abuse: a comprehensive textbook. Baltimore: Williams and Wilkins, 1992:550-561.
133. Babst DV, Newman S, Gordon NB, Warner A. Driving records of methadone maintained patients in New York State. Albany, NY: New York State Narcotic Control Commission, 1973.
134. Gordon NB. Influence of narcotic drugs on highway safety. Accid Anal Prev 1976;8:3-7.
135. Dole VP. Narcotic addiction, physical dependence and relapse. N Engl J Med 1972;286:988-992.
136. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics, 7th ed. New York: Macmillan, 1985:491-531.
137. Martin WR, Jasinski DR. Physiological parameters of morphine dependence in man-tolerance, early abstinence, protracted abstinence. J Psychol Res 1969;7:9-17.
138. Rinaldi RC, Steindler EM, Wilford BB, Goodwin D. Clarification and standardization of substance abuse terminology. JAMA 1988;259:555-557.
139. World Health Organization. Technical report no. 516: youth and drugs. Geneva: World Health Organization, 1973.
140. Halpern LM, Robinson J. Prescribing practices for pain in drug dependence: a lesson in ignorance. Adv Alcohol Subst Abuse 1985;5:184-197.
141. Redmond DE, Krystal JH. Multiple mechanisms of withdrawal from opioid drugs. Annu Rev Neurosci 1984;7:443-478.
142. Brodner RA, Taub A. Chronic pain exacerbated by long-term narcotic use in patients with nonmalignant disease: clinical syndrome and treatment. Mt Sinai J Med 1978;45:233-237.
143. Matthew N. Drug-induced headache. Neurol Clin 1990;8:903-912.
144. Saper JR. Daily chronic headache. Neurol Clin 1990;8:891-902.
145. Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics, 7th ed. New York: Macmillan, 1985:532-581.
146. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., revised. Washington, DC: American Psychiatric Association, 1994.
147. Sees KL, Clark HW. Opioid use in the treatment of chronic pain: assessment of addiction. J Pain Symptom Manage 1993;8:257-264.
148. Portenoy RK. Iatrogenic addiction. In: Jaffe JH, ed. The encyclopedia of drugs and alcohol. New York: Macmillan, 1996 (in press).
149. Weissman DE, Haddox JD. Opioid pseudoaddiction: an iatrogenic syndrome. Pain 1989;36: 363-366.
150. Rayport M. Experience in the management of patients medically addicted to narcotics. JAMA 1954;156:684-691.
151. Simpson DD, Savage LJ, Lloyd MR. Follow-up evaluation of treatment of drug abuse during 1969 to 1972. Arch Gen Psychiatry 1979;36:772-780.
152. Vallaint GE. A 20-year follow-up of New York narcotic addicts. Arch Gen Psychiatry 1973;29:237-241.
153. Wikler A. Opioid dependence: mechanisms and treatment. New York: Plenum, 1980.
154. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992;8:77-85.
155. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980;302:123.
156. Perry S, Heidrich G. Management of pain during debridement: a survey of US burn units. Pain 1982;13:267-280.
157. Medina JL, Diamond S. Drug dependency in patients with chronic headache. Headache 1977;17: 12-14.
158. Chapman CR, Hill HF. Prolonged morphine self-administration and addiction liability: evaluation of two theories in a bone marrow transplant unit. Cancer 1989;63:1636-1644.
159. Regier DA, Meyers JK, Kramer M, et al. The NIMH epidemiologic catchment area program. Arch Gen Psychiatry 1984;41:934-958.
160. Graeven DB, Folmer W. Experimental heroin users: an epidemiologic and psychosocial approach. Am J Drug Alcohol Abuse 1977;4:365-375.
161. Robins LN, Davis DH, Nurco DN. How permanent was Vietnam drug addiction? Am J Public Health 1974;64:38-43.
162. Hill HE, Haertzen CA, Glaser R. Personality characteristics of narcotic addicts as indicated by the MMPI. J Gen Psychol 1960;62:127-139.
163. Hill HE, Haertzen CA, Davis H. An MMPI factor analytic study of alcoholics, narcotic addicts and criminals. Qu J Stud Alcohol 1962;23:411-431.
164. Jarvik LF, Simpson JH, Guthrie D, Liston EH. Morphine, experimental pain and psychological reactions. Psychopharmacology 1981;75:124-131.
165. Jaffe JH. Misinformation: euphoria and addiction. In: Hill CS, Fields W, eds. Advances in pain research and therapy, vol 11. New York: Raven, 1989:163-174.
166. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983;13:180-185.
167. Grove WM, Eckert ED, Heston L, Bouchard TJ, Segal N, Lykken DT. Heritability of substance abuse and antisocial behavior: a study of monozygotic twins reared apart. Biol Psychiatry 1990;27: 1293-1304.
168. Anthenelli RM, Schuckit MA. Genetics. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance abuse: a comprehensive textbook. Baltimore: Williams and Wilkins, 1992:39-50.
169. Burchman SL, Pagel PS. Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. J Pain Symptom Manage 1995;10:556-563.